Testing New Formats for the Presentation of Research Evidence to Health Care Managers and Policy Makers
5. Mai 2020 aktualisiert von: Unity Health Toronto
A Randomized Trial to Compare the Effects of a Novel Versus Traditional Systematic Review Format on the Ability of Health Care Managers and Policy Makers to Understand and Apply Evidence
The purpose of this project is to identify and use our knowledge on the barriers and facilitators to using systematic reviews (SR) by health care managers (HCM) and policy markers (PM) to develop and test a novel format for presentation of SR for HCM and PM.
We will invite HCM and PM from hospitals and regional authorities in Ontario, Alberta, and British Columbia to participate in a randomized-control trial.
Participants will receive a link to an online consent survey, and then be randomly allocated to receive access to a novel SR or its traditional presentation.
There is no time limit to completing the task, and participants are able to save their responses and finish later.
Participants are able to withdraw from the study by not completing the task.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Despite advances in the conduct and reporting of traditional systematic reviews, current evidence suggests that they are used infrequently by health care managers and policy makers in decision making. Managers and policy makers have suggested that concise presentation positively affects the use of systematic reviews. The purpose of this randomized controlled trial is to assess the impact of a traditional systematic review format compared with the innovative format on the ability of health care managers and policy makers to understand the evidence in the review and apply it to a relevant health care decision making scenario.
The two end-user groups have different formatting needs and we will therefore run 2 parallel studies, randomizing each group separately. Once participants have consented to participate, a computer generated randomization process will allocate them to one of 2 arms (1:1 ratio). Participants will either receive either a traditional format or a novel format. Unequal block randomization will be used and allocation will be concealed through central assignment. Outcomes assessors will be blinded and participants will be blinded to the citation of the review so that the traditional version will not be easily accessible in its original format from the relevant journal.
This study will be the first study to engage health care managers and policy makers in the testing of formats for presentation of research evidence relevant to their needs. The results of the project will help increase the uptake of systematic review results in health care management policy decision-making, ultimately leading to informed decision making and positively impacting the health of Canadians.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
257
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M5B 1W8
- St. Michael's Hospital
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Health care managers from the Alberta SCNs, CAHO in Ontario, the RHAs and AQESSS in Quebec and RHAs from BC will be invited to participate.
- Policy makers/analysts from the Ontario, BC, Alberta and Quebec Ministries of Health
Exclusion Criteria:
- Health care managers or policy makers who are unwilling or unable to give informed consent.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Novel systematic review format
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
|
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
|
|
Kein Eingriff: Traditional systematic review format
Control participants will be asked to read and answer questions using a traditional systematic review format.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format
Zeitfenster: This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
The proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format to the scenario as measured by agreement with an expert panel's recommendation.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of appropriate application of the evidence.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Comprehension of the review
Zeitfenster: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Comprehension of the review - defined as the proportion of participants (health care managers or policy makers) who accurately define the bottom line from the systematic review as defined by an expert panel.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of the bottom line from the systematic review.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Intention to use evidence
Zeitfenster: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Intention to use evidence - collected through a 12-item likert scale survey.
The survey has good face validity amongst policy makers and managers.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Perceived tentativeness of research findings
Zeitfenster: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Perceived tentativeness of research findings - collected through a 6-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Provisional opinion about the intervention
Zeitfenster: This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Provisional opinion about the intervention - collected through a 14-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Sharon e Straus, Unity Health Toronto
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
16. Mai 2017
Primärer Abschluss (Tatsächlich)
30. November 2019
Studienabschluss (Tatsächlich)
30. November 2019
Studienanmeldedaten
Zuerst eingereicht
5. Januar 2017
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
1. Februar 2017
Zuerst gepostet (Schätzen)
2. Februar 2017
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
7. Mai 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
5. Mai 2020
Zuletzt verifiziert
1. Mai 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- SMH-312381
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .